| 17.24 0.37 (2.19%) | 06-24 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 21.47 | 1-year : | 23 |
| Resists | First : | 18.38 | Second : | 19.69 |
| Pivot price | 17.44  |
|||
| Supports | First : | 16.27 | Second : | 13.53 |
| MAs | MA(5) : | 17.13 |
MA(20) : | 17.71 |
| MA(100) : | 16.09 |
MA(250) : | 20.43 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 21.7 |
D(3) : | 24.3 |
| RSI | RSI(14): 48 |
|||
| 52-week | High : | 27.89 | Low : | 12.84 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ STVN ] has closed above bottom band by 42.1%. Bollinger Bands are 14.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 17.44 - 17.53 | 17.53 - 17.62 |
| Low: | 16.73 - 16.82 | 16.82 - 16.91 |
| Close: | 17.1 - 17.24 | 17.24 - 17.38 |
Stevanato Group S.p.A. is dedicated to engineering, manufacturing, and distributing integrated solutions for the pharmaceutical and healthcare sectors. Its core offerings span a wide array of products, including containment solutions, drug delivery systems, and medical devices, alongside diagnostic and analytical support. The company also produces specialized machinery for tasks such as visual inspection, assembly, packaging, and glass formation. Established in 1949, the company's main operations are situated in Piombino Dese, Italy, functioning as a subsidiary of Stevanato Holding S.R.L.
Thu, 11 Jun 2026
Stevanato: HVS Momentum Overshadows Engineering Weakness, Offering Compelling Upside - Seeking Alpha
Thu, 11 Jun 2026
Is Stevanato Group S.p.A. (STVN) A Good Stock To Buy Now? - Yahoo Finance
Mon, 08 Jun 2026
Stevanato Group S.p.A. (STVN): Analyst Consensus Highlights 32.12% Potential Upside - DirectorsTalk Interviews
Mon, 08 Jun 2026
Stevanato Group Introduces Deora™, a Pen Injector for Subcutaneous Delivery in Diabetes and Weight Management - Business Wire
Wed, 03 Jun 2026
Stevanato Group Announces Results of Ordinary and Extraordinary Shareholders’ Meeting - Stevanato Group S.p.A. (STVN)
Thu, 07 May 2026
Stevanato Group (STVN) Q1 Earnings and Revenues Beat Estimates - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 50 (M) |
| Shares Float | 49 (M) |
| Held by Insiders | 1.5 (%) |
| Held by Institutions | 96.5 (%) |
| Shares Short | 1,010 (K) |
| Shares Short P.Month | 886 (K) |
| EPS | 0.58 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.46 |
| Profit Margin | 11.7 % |
| Operating Margin | 14.2 % |
| Return on Assets (ttm) | 5.2 % |
| Return on Equity (ttm) | 9.5 % |
| Qtrly Rev. Growth | 6.5 % |
| Gross Profit (p.s.) | 7.07 |
| Sales Per Share | 24.14 |
| EBITDA (p.s.) | 5.8 |
| Qtrly Earnings Growth | 2.9 % |
| Operating Cash Flow | 262 (M) |
| Levered Free Cash Flow | -57 (M) |
| PE Ratio | 29.22 |
| PEG Ratio | 3.5 |
| Price to Book value | 2.66 |
| Price to Sales | 0.71 |
| Price to Cash Flow | 3.27 |
| Dividend | 0.05 |
| Forward Dividend | 0 |
| Dividend Yield | 0.3% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|